The effects of insulin sensitizers on the cardiovascular risk factors in women with polycystic ovary syndrome.
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in pre-menopausal women characterized by menstrual cycle disturbances, chronic anovulation, and clinical and/or biochemical hyperandrogenism. Although, the primary etiology of PCOS remains unknown, insulin resistance/hyperinsulinemia plays a pivotal role in the pathogenesis of the syndrome. A growing body of recent data support that women with PCOS have displayed an increased prevelance of cardiovascular disease (CVD) risk factors putting potentially at a hight risk for heart disease. Most of these CVD risk factors are etiologically correlated with insulin resistance/hyperinsulinemia, highlighting the role of insulin sensitizers in the therapeutic quiver for the chronic treatment of PCOS. In this review, we discuss the current literature on the CVD risk factors in PCOS and the influence of insulin sensitizers upon these risk factors.
Kassi
E
E
Department of Biological Chemistry, Laiko General Hospital, University of Athens Medical School, Athens, Greece.
Diamanti-Kandarakis
E
E
D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000209:etiology*; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000378:metabolism; D007328:Insulin / Q000378:metabolism*; D008954:Models, Biological; D011085:Polycystic Ovary Syndrome / Q000150:complications* / Q000188:drug therapy* / Q000378:metabolism; D012307:Risk Factors
D007004:Hypoglycemic Agents; D018836:Inflammation Mediators; D007328:Insulin